Regenerative Financing to Accelerate Health Innovation
Summary
In 2025, Catalytic Impact Foundation (CIF) committed to grow its investment capital platform to $50 million within five years to fund 60 early-stage companies with cutting-edge innovations in areas of health care where traditional capital falls short, including children’s women’s, brain and mental health, and rare diseases. CIF targets innovations that will expand access to quality health care in underserved communities. Collectively, these companies potentially can save 3 million lives and improve quality of life for 150 million patients. With this commitment, CIF will dramatically scale the size and impact of its investment platform and the educational and mentoring support it provides to portfolio partners to de-risk and position companies to overcome the gap between research and development and deployment in the commercial market. This has the potential to increase the availability of products and services and improve treatment and care for areas of unmet health needs.
Approach
The Catalytic Impact Foundation (CIF) , commits to grow its investment capital platform to $50M within 5 years to fund 60 early-stage companies with cutting-edge innovations in areas of healthcare where traditional capital falls short. Collectively, these companies potentially can save 3M lives and improve 150M patients’ quality of life. Collaborating with strategic partners, CIF will also expand its Company Support Ecosystem to include coaching, mentorship, and networking, to provide resources and skill development to maximize founder success. Over the next four years, efforts will focus on addressing the high unmet needs and health inequities in North America, with future plans to expand to other regions.
CIF has built a philanthropic regenerative investment platform to accelerate disruptive innovations in healthcare. CIF invests in early-stage companies with transformational technologies addressing areas of high unmet need in health lacking sufficient funding from traditional sources. CIF also targets innovations that will expand access to quality healthcare in underserved communities. CIF has honed its model to deliver tangible results, accumulating deep experience and an outstanding track record. CIF’s core investment team brings 150 years of collective experience in venture capital, private equity, life science and healthcare due diligence, and biotech consulting.
The team currently evaluates more than 1,000 companies annually, and has invested in more than 50 companies. CIF has built relationships with many early-stage funding organizations to catalyze additional capital for its portfolio companies. CIF is supported by an expansive network of expert advisors from industry, entrepreneurship, research, clinical medicine, finance, regulatory, and government.
With this commitment, CIF will dramatically scale the size and impact of its investment platform, building on its proof-of-concept phase that has shown outstanding results. In addition, CIF will expand its Company Support Ecosystem to maximize the educational and mentoring support to de-risk and accelerate company growth. This has the potential to increase the availability of products and services to address areas of unmet health needs and improve treatment and care.
Action Plan
Implementation Steps:
Scaling the CIF Fund: CIF will launch focused initiatives targeting urgent medical needs—where innovation can lead to breakthroughs in treatment, diagnostics, disease management, and access. CIF will identify funding partners who have aligned interests, and will develop an investment thesis, timeline, impact statement, and milestones to measure and report on progress.
Expanding Company Support Ecosystem: CIF will build the Catalytic Academy, an online founders training hub with live workshops, leveraging CIF’s extensive network of experts. In addition, CIF will create a library of recorded content. Finally, CIF will develop an advisor matchmaking initiative to connect founders with expert mentors.
Quarterly Milestones (results are cumulative) :
Year 1: 2026
Q1: Recruit experts to run workshops;
Q2: Announce partnerships with advisor/mentor organizations;
Q3: Match 5 advisors with founders;
Q4: Invest in 10-12 new companies, with potential to save 600K & improve 30M lives.
Year 2: 2027
Q1: Develop content library/training modules;
Q2: Complete programming with 15 executives;
Q3: Achieve 3 new commercialized solutions/products;
Q4: Invest in 20-24 companies, with potential to save 1.2M & improve 60M lives.
Year 3: 2028
Q1: Match 15 advisors with founders;
Q2: Complete programming with 20 executives;
Q3: Achieve 6-8 commercialized solutions/products;
Q4: Invest in 30-36 companies, with potential to save 1.8M & improve 90M lives.
Year 4: 2029
Q1: Match 25 advisors with founders;
Q2: Complete programming with 25 executives;
Q3: Achieve 12-15 commercialized solutions/products;
Q4: Invest in 40-48 companies, with potential to save 2.4M & improve 120M lives.
Year 5: 2030
Q1: Exit 6-8 companies, reinvested funds forward into new companies/innovations;
Q2: Match 40 advisors with founders;
Q3: Achieve 20-25 commercialized solutions/products;
Q4: Invest in 50-60 companies, with potential to save 3.0M lives & improve 150M lives.
Background
Serious funding gaps exist in the U.S. innovation ecosystem, creating a treatment gap. Long-term, self-sustaining funding models are needed to solve overlooked and underfunded healthcare needs, and to improve availability and access to care.
Vital areas of healthcare, such as children’s, women’s, and brain and mental health, and rare diseases, are consistently underfunded, and medical needs often go unaddressed. Due to insufficient funding to advance solutions, patients and families suffer, with few options when faced with daunting healthcare challenges.
Additionally, a 15-year life expectancy gap separates America’s richest and poorest communities. Thirty million Americans live in “healthcare deserts”, where poor access shortens lives. Promising technologies can narrow this gap, but funding remains challenging.
These funding gaps have consequences. Since 2021, the FDA has approved 200+ cancer drugs for adults, but only 6 for pediatric cancer, the leading disease-related cause of death among children. Annually, 1,800 U.S. children die, yet only 4% of federal cancer funding targets pediatrics. In women’s health, only 4% of venture capital (VC) goes to innovation, although women spend 25% more of their lives than men in poor health, unrelated to living longer.
The funding problem is urgent. Market conditions that were already historically challenging are creating a perfect storm. Economic uncertainty and a sharp decline in exits has made it difficult for VCs to raise new funds. (Exits plunged from $842B in 2021 to $149B in 2024.) Accordingly, VCs are hesitant to make new investments. Early-stage investments have hit a 12-year low, with half of funding now going to AI companies, while VC firms have been conserving cash to support existing portfolio companies.
While federal grants fund basic research, and VCs fund high-return sectors, potentially transformational early-stage companies too often succumb to the “Valley of Death”, and many challenging conditions go undertreated.
Progress Update
Partnership Opportunities
CIF seeks partners who will provide funding, expertise, and exposure, enabling CIF to expand its successful model.
Funding Partners: CIF will seek partners to finance growth of its Catalytic Innovation Fund, CIF’s regenerative investment platform that will continue in perpetuity. Partnerships will be designed to create lasting, multi-year, financing and impact, focused on areas of high unmet medical needs or specific underserved communities.
Company Support Partners: CIF will work with leading accelerators/incubators, mentor networks, and training platforms to incorporate – and build upon – existing high-quality systems, programs and content. CIF will collaborate with top-tier industry organizations to access experts and opinion leaders, and proven training modules, to help support and educate founders.
Media & Reporting Partners: CIF will seek firms in communications, media, consulting and PR to help spotlight success stories, amplify CIF’s mission, and grow awareness of this critical work.,Strategic Partnerships: CIF will engage partners in this commitment, with potential partners being philanthropists, foundations, healthcare leaders, accelerators, and other mission-aligned organizations. CIF anticipates three types of partnerships.
Funding Partners: For funding partners who support a specific initiative, CIF offers outcomes aligned with each partner’s specific goals. At a partner’s discretion, they may have hands-on involvement in sourcing, screening, evaluating and structuring investments, developing expertise and skills to replicate and extend impact. CIF also will share their Impact Measurement and Reporting System to regularly measure key metrics, predictive data, and substantive outcomes.
Company Support Partners: CIF will highlight and amplify the work of partners, enabling them to build their brands, expand networks, reach new clients, and access professional development opportunities.
Media & Reporting Partnerships: CIF will provide access to data, outcomes, key opinion leaders, and success stories, enabling media and reporting organizations to develop insightful and engaging content and reporting.